Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc. is exhibiting a positive outlook due to its innovative pipeline of anticancer agents, particularly with the promising performance of VS-7375 in the competitive KRAS G12D landscape, where it is considered a best-in-class candidate. The drug has garnered strong enthusiasm among physicians and is experiencing better response rates, with low discontinuation rates compared to historical MEK inhibitors, indicating potential for substantial growth. Additionally, the observed effectiveness in both KRAS mutant and wild-type tumors, along with the ability for patients to remain on treatment, supports broader clinical adoption and a favorable market position.

Bears say

Verastem Inc. has experienced continuous operating losses since its inception, raising concerns about its ability to achieve profitability in the foreseeable future. The challenges associated with KRAS inhibition, particularly in colon cancer, are highlighted by lower overall response rates and weaker responses to treatments in patients with specific KRAS mutations compared to others. Furthermore, delays in regulatory approval processes could adversely affect the company's prospects and lead to further negative sentiment surrounding its stock performance.

Verastem (VSTM) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.